Icecure Medical (ICCM) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
IceCure Medical Ltd. has been granted a new U.S. patent for its innovative cryogenic pump technology, expanding the company’s leading position in cryoablation technologies for tumor treatment. With over 50 patents worldwide, this latest patent enhances IceCure’s platform, allowing broader applications in medical procedures and indicating strong potential for future growth. The company’s advanced cryoablation systems, including the flagship ProSense system, offer a minimally invasive alternative for tumor removal and are sold globally.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
